Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

56.84 -0.78 (-1.35%)
Streaming Delayed Price Updated: 12:17 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
90 91 Next >
News headline image
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up? 
Via The Motley Fool
News headline image
Rolling Into Spreads: Extend Profit Potential with Lower Risk ↗
Learn how a vertical spread options strategy can help reduce risk, lock in gains, and stay invested in winning trades. 
Via InvestorPlace
News headline image
3 Unpopular Stocks with Questionable Fundamentals
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? ↗
Bristol Myers Squibb leans on specialty medicines and a discounted valuation, while Johnson & Johnson boasts industry-leading margins and cash flow. 
Via The Motley Fool
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Play with Cautionary Notes ↗
Via Chartmill
Bristol-Myers Squibb Co (NYSE:BMY): High Yield and Solid Profitability, but Growth Concerns Loom ↗
Via Chartmill
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trials for Multiple Sclerosis
Via Investor Brand Network
News headline image
The Quest to Repair What Multiple Sclerosis Takes Away
From BioMedWire
Via GlobeNewswire
News headline image
3 Reasons to Buy Bristol Myers Squibb Stock ↗
Fears about a looming patent cliff have dragged on the shares. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock with Solid Fundamentals and 2 We Avoid
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ... 
Via StockStory
Topics Stocks
News headline image
Bristol Myers Squibb to Report Results for Second Quarter 2026 on July 30, 2026
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Dividend Stocks to Hold for the Long Haul ↗
They have a habit of consistently raising their payouts. 
Via The Motley Fool
Topics Intellectual Property
News headline image
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. ↗
Bristol Myers Squibb has a well-above-market yield of 4.5% and it appears reasonably safe. 
Via The Motley Fool
Topics Bonds Intellectual Property
News headline image
Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue. ↗
"Productivity initiatives" could prove key in maintaining this pharma company's decades-long dividend growth streak. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Mariska Hargitay Partners with Bristol Myers Squibb for “Investigating Myeloma” Awareness Campaign to Honor Her Father 20 Years After Losing Him to the Disease
From Bristol Myers Squibb
Via Business Wire
News headline image
Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500? ↗
For a solid yield and strong upside potential, this pharmaceutical stock is worth considering. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock ↗
What does this smart money investor see that the market is missing? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer? ↗
Durability, not yield, is the deciding factor. 
Via The Motley Fool
News headline image
3 Value Stocks We Think Twice About
Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ... 
Via StockStory
News headline image
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now? ↗
Whichever one you choose, you'll need patience before you can see solid returns. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell Carcinoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks ↗
Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x. 
Via The Motley Fool
Topics Intellectual Property
Explore the top gainers and losers within the S&P500 index in today's session. ↗
Via Chartmill
News headline image
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Spotting Winners: Bristol-Myers Squibb (NYSE:BMY) And Branded Pharmaceuticals Stocks In Q1
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how branded pharmaceutical... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
From Bristol Myers Squibb
Via Business Wire
News headline image
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
News headline image
1 Surging Stock with Promising Prospects and 2 We Ignore
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
90 91 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.